KYMR
Company Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.20M | 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0 |
| Net Income | (311.40M) | (223.86M) | (146.96M) | (154.81M) | (100.22M) | (45.59M) | (41.29M) | (21.47M) |
| EPS | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -0.99 | -0.93 | -0.48 |
| Free Cash Flow | (234.34M) | (207.34M) | (137.31M) | (155.92M) | (130.54M) | 79.03M | 17.37M | (19.22M) |
| FCF / Share | -2.78 | -2.76 | -2.35 | -2.89 | -2.72 | 1.77 | 0.39 | -0.43 |
| Operating CF | (232.89M) | (194.50M) | (102.83M) | (153.09M) | (128.95M) | 88.13M | 17.91M | (17.86M) |
| Total Assets | 1.74B | 978.03M | 575.76M | 603.13M | 605.90M | 487.18M | 116.70M | 44.23M |
| Total Debt | 82.25M | 87.76M | 84.67M | 17.34M | 17.96M | 17.99M | 21.19M | 695,000 |
| Cash & Equiv | 357.01M | 120.26M | 109.97M | 68.39M | 47.98M | 31.00M | 76.02M | 41.26M |
| Book Value | 1.58B | 835.62M | 394.97M | 490.15M | 459.64M | 283.89M | (74.41M) | (34.44M) |
| Return on Equity | -0.20 | -0.27 | -0.37 | -0.32 | -0.22 | -0.16 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.37M | 2.86M | 2.76M | 11.48M | 22.10M | 7.39M | 3.74M | 25.65M | 10.29M | 47.88M | 4.73M | 16.51M |
| Net Income | (69.23M) | (87.03M) | (82.17M) | (76.61M) | (65.58M) | (70.75M) | (62.49M) | (42.06M) | (48.56M) | (14.37M) | (52.87M) | (38.80M) |
| EPS | -0.71 | -0.98 | -0.94 | -0.95 | -0.82 | -0.88 | -0.82 | -0.58 | -0.69 | -0.25 | -0.90 | -0.67 |
| Free Cash Flow | (89.27M) | (66.85M) | (27.29M) | (60.58M) | (79.62M) | (62.72M) | (50.00M) | (47.62M) | (46.99M) | (3.58M) | (39.72M) | (46.02M) |
| FCF / Share | -0.92 | -0.79 | -0.31 | -0.75 | -0.99 | -0.78 | -0.66 | -0.65 | -0.66 | -0.06 | -0.68 | -0.79 |
| Operating CF | (88.84M) | (66.75M) | (27.11M) | (59.88M) | (79.15M) | (61.78M) | (50.19M) | (42.94M) | (39.59M) | 8.04M | (31.65M) | (35.26M) |
| Total Assets | 1.67B | 1.74B | 1.10B | 1.13B | 918.31M | 978.03M | 1.03B | 826.02M | 868.25M | 575.76M | 552.38M | 581.95M |
| Total Debt | 80.47M | 82.25M | 84.00M | 85.71M | 86.33M | 87.76M | 88.23M | 88.18M | 87.02M | 84.67M | 80.84M | 75.06M |
| Cash & Equiv | 144.09M | 357.01M | 112.95M | 335.82M | 89.97M | 120.26M | 110.72M | 67.61M | 93.51M | 109.97M | 81.05M | 52.39M |
| Book Value | 1.54B | 1.58B | 946.26M | 971.48M | 786.23M | 835.62M | 892.93M | 684.92M | 711.20M | 394.97M | 395.54M | 435.43M |
| Return on Equity | -0.04 | -0.06 | -0.09 | -0.08 | -0.08 | -0.08 | -0.07 | -0.06 | -0.07 | -0.04 | -0.13 | -0.09 |
